×
About 210 results

ALLMedicine™ Pediatric Hodgkin Lymphoma Center

Research & Reviews  71 results

Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for p...
https://doi.org/10.1080/08880018.2022.2044418
Pediatric Hematology and Oncology; Palayullakandi A, Trehan A et. al.

Mar 11th, 2022 - ABVD regimen for Hodgkin lymphoma (HL) is frequently used in children and young adults in low-middle income countries (LMIC). The feasibility and safety data for 'non-ABVD' protocols from LMIC is limited. The retrospective study was conducted in a...

The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience.
https://doi.org/10.1080/10428194.2022.2045602
Leukemia & Lymphoma; Rodriguez-Hernandez A, Giulino-Roth L

Mar 8th, 2022 - The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience.|2022|Rodriguez-Hernandez A,Giulino-Roth L,|

Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vi...
https://doi.org/10.1002/pbc.29601
Pediatric Blood & Cancer; de Armas S, Huertas-Ayala C et. al.

Feb 22nd, 2022 - Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC...

Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and ou...
https://doi.org/10.1016/j.radonc.2022.01.016
Radiotherapy and Oncology : Journal of the European Socie... Tringale KR, Modlin LA et. al.

Feb 2nd, 2022 - With high survival rates for pediatric Hodgkin lymphoma (HL), attention has turned to minimizing treatment-related morbidity and mortality. Chemotherapy and dose of radiation to organs at risk (OARs) contribute to elevated risks of secondary malig...

Neutrophil-to-Lymphocyte Ratio and Ferritin as Measurable Tools for Disease Burden and ...
https://doi.org/10.1097/MPH.0000000000002346
Journal of Pediatric Hematology/oncology; Jan S, Mustafa O et. al.

Oct 17th, 2021 - Pediatric Hodgkin lymphoma (HL) has been treated successfully with risk-adapted and response-adapted therapy. While risk factors like Ann Arbor staging system, B symptoms, bulky disease, and erythrocyte sedimentation rate were measured objectively...

see more →

Guidelines  1 results

Implementation of contemporary radiation therapy planning concepts for pediatric Hodgki...
https://doi.org/10.1016/j.prro.2014.05.003
Practical Radiation Oncology; Hodgson DC, Dieckmann K et. al.

Nov 22nd, 2014 - The optimal management of children with Hodgkin lymphoma (HL) should limit the risk of treatment-related toxicity without compromising disease control. Consequently, increasing effort is being directed to retaining the demonstrated efficacy of rad...

see more →

Clinicaltrials.gov  2 results

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
https://clinicaltrials.gov/ct2/show/NCT04213209

Oct 7th, 2021 - The drug being tested in this survey is called Brentuximab Vedotin intravenous infusion 50 mg. This intravenous infusion is being tested to treat adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding...

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
https://clinicaltrials.gov/ct2/show/NCT03500133

Aug 6th, 2019 - This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects. Patients of both genders, between 2 and 18 years, with newly diagnosed clas...

see more →

News  10 results

Awareness Increases of Unique Needs of AYA Lymphoma Patients
https://www.onclive.com/view/awareness-increases-of-unique-needs-of-aya-lymphoma-patients

Oct 6th, 2021 - Lisa G. Roth, MD As awareness of the unique needs of adolescents and young adults (AYA) with cancer increases, there are now clinical trials in Hodgkin lymphoma specifically focused on this patient population. For example, a phase II trial is in...

Incorporation of Brentuximab Vedotin Into Frontline Pediatric High-Risk Hodgkin Lymphoma Treatment Yields Favorable Outcomes
https://www.onclive.com/view/incorporation-of-brentuximab-vedotin-into-frontline-pediatric-high-risk-hodgkin-lymphoma-treatment-yields-favorable-outcomes

May 21st, 2021 - The integration of the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) into the frontline treatment of pediatric patients with high-risk Hodgkin lymphoma resulted in favorable clinical outcomes with promising tolerability an...

Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines
https://www.medscape.com/viewarticle/939302

Oct 19th, 2020 - NEW YORK (Reuters Health) - The diagnosis of pediatric Hodgkin lymphoma requires an excisional or incisional biopsy and immunohistochemistry (IHC) evaluation, and its management depends largely on the clinical stage and risk group, according to ne...

Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines
https://www.staging.medscape.com/viewarticle/939302

Oct 19th, 2020 - NEW YORK (Reuters Health) - The diagnosis of pediatric Hodgkin lymphoma requires an excisional or incisional biopsy and immunohistochemistry (IHC) evaluation, and its management depends largely on the clinical stage and risk group, according to ne...

Experts Call for Increased Awareness of Existing Racial Disparities in RCC, Other Malignancies
https://www.onclive.com/view/experts-call-for-increased-awareness-of-existing-racial-disparities-in-cancer-care-and-survival

Oct 7th, 2020 - Despite the numerous reports detailing racial differences in cancer outcomes and care over the years, the reasons underlying these disparities continue to be under deep exploration. Awareness of the factors at play is needed to improve understandi...

see more →